Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008–2013

Malaria Journal

Research

Fang Huang¹  Mei Li¹  Lin-hua Tang¹  Jia-zhi Wang²  Xiang-rui Guo³  Ying-xue Lin³  Jian-Wei Xu⁴  Chun-fu Li⁴  Heng-ye Wang⁴  Ren-hua Nie⁴  Heng-lin Yang⁴  Xing-liang Li⁴  Hui Liu⁴ 

[1] National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 200025, Shanghai, China;Tengchong County Center for Disease Control and Prevention, Tengchong, China;Yangjiang County Center for Disease Control and Prevention, Tengchong, China;Yunnan Institute of Parasitic Diseases, 665000, Puer, China;

关键词: Plasmodium vivax;    Chloroquine;    Resistance;    China-Myanmar border;   

DOI  :  10.1186/1475-2875-13-364

 received in 2014-06-26, accepted in 2014-09-12,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundPlasmodium vivax is the most widespread of the malaria parasites infecting human hosts. In malaria-eliminating settings, both imported and local malaria predominantly occurs in border areas, and most of them are P. vivax. Chloroquine (CQ) is the first-line drug for P. vivax treatment in China. To understand CQ sensitivity in P. vivax, in vivo monitoring of CQ resistance was conducted along the China-Myanmar border from 2008 to 2013.MethodsEligible patients with mono-infections of P. vivax were recruited to this study after obtaining full informed consent. CQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients were followed up for 28 days. PCR was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome and sensitivity were classified according to the WHO recommended standards.Results603 patients were completed valid follow-up. The fever clearance time and asexual parasite clearance times were, respectively, 22.2 ± 10.2 and 38.1 ± 12.6 hours. 594 (98.5%) patients were adequate clinical and parasitological response (ACPR), and nine (1.5%) patients, who were late clinical failure (LCF) or resistant response level I (RI), were imported from the neighbouring districts of Myanmar.ConclusionIn terms of efficacy, CQ is still effective for vivax malaria treatment. Plasmodium vivax CQ sensitivity had not significantly changed along the China-Myanmar border of Yunnan Province, China.

【 授权许可】

Unknown   
© Liu et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.